We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NASDAQ:AZN | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.355 | -0.46% | 76.055 | 76.06 | 76.07 | 76.41 | 75.87 | 76.26 | 1,187,824 | 15:23:40 |
From May 2021 to May 2024
By Ian Walker
AstraZeneca PLC said Thursday that ALXN1840 met the primary endpoint in a FoCus Phase 3 trial for Wilson disease, showing an improvement in copper mobilization from tissues.
The pharmaceutical giant said that ALXN1840 demonstrated about three times more copper mobilization from tissues than standard-of-care treatments.
Wilson disease is a rare and progressive genetic condition in which the body's pathway for removing excess copper is compromised.
Separately AstraZeneca said that Forxiga has been approved in Japan for the treatment of chronic kidney disease in patients with and without type-2 diabetes.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
August 26, 2021 02:32 ET (06:32 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
